These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 25279715)

  • 1. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.
    Lisboa-Neto G; Noble CF; Pinho JR; Malta FM; Gomes-Gouvêa MS; Alvarado-Mora MV; da Silva MH; Leite AG; Piccoli LZ; Rodrigues FK; Carrilho FJ; Mendes-Correa MC
    Antivir Ther; 2015; 20(3):281-7. PubMed ID: 25279715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
    Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D
    HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
    Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
    J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients.
    Cao Y; Bao Y; Xia W; Wu H; Wei F; Zhang Y; Zhang R; Xu X
    Clin Res Hepatol Gastroenterol; 2016 Nov; 40(5):597-604. PubMed ID: 27016893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals.
    Nguyen LT; Gray E; Dean J; Carr M; Connell J; De Gascun C; Nguyen LA; O'Leary A; Bergin C; Hall W; Norris S
    Antivir Ther; 2015; 20(8):865-9. PubMed ID: 25920764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients.
    Bartolini B; Giombini E; Zaccaro P; Selleri M; Rozera G; Abbate I; Comandini UV; Ippolito G; Solmone M; Capobianchi MR
    Virus Res; 2013 Nov; 177(2):205-8. PubMed ID: 23954579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
    Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
    Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in São Paulo state.
    Moreira RC; de Torres Santos AP; Lisboa-Neto G; Mendes-Corrêa MCJ; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; de Castro VFD; Pinho JRR
    Arch Virol; 2018 Oct; 163(10):2757-2764. PubMed ID: 29961118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of clinical predictors of naturally occurring NS3/NS4A protease polymorphism in genotype 1 hepatitis C virus mono and HIV co-infected patients.
    Lisboa Neto G; Malta FM; Gomes-Gouvêa MS; Noble CF; Romano CM; Rebello Pinho JR; Silva MH; Leite AGB; Piccoli LZ; Carrilho FJ; Mendes-Correa MC
    J Med Virol; 2017 Dec; 89(12):2249-2254. PubMed ID: 28700085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection.
    Tavares RCF; Feldner ACCA; Pinho JRR; Uehara SNO; Emori CT; Carvalho-Filho RJ; Silva ISS; Santana RAF; de Castro VFD; Castoli GTF; Cristovão CU; Ferraz MLCG
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):754-758. PubMed ID: 28234637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
    Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
    Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.
    de Carvalho IM; Alves R; de Souza PA; da Silva EF; Mazo D; Carrilho FJ; Queiroz AT; Pessoa MG
    J Med Virol; 2014 Oct; 86(10):1714-21. PubMed ID: 25042789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.
    Paolucci S; Fiorina L; Piralla A; Gulminetti R; Novati S; Barbarini G; Sacchi P; Gatti M; Dossena L; Baldanti F
    Virol J; 2012 Oct; 9():245. PubMed ID: 23095680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
    Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
    PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1.
    Costa VD; Delvaux N; Brandão-Mello CE; Nunes EP; de Sousa PSF; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):700-706. PubMed ID: 30880098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
    Berger KL; Triki I; Cartier M; Marquis M; Massariol MJ; Böcher WO; Datsenko Y; Steinmann G; Scherer J; Stern JO; Kukolj G
    Antimicrob Agents Chemother; 2014; 58(2):698-705. PubMed ID: 24217701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors.
    Bagaglio S; Messina E; Hasson H; Merli M; Andolina A; Lazzarin A; Uberti-Foppa C; Morsica G
    New Microbiol; 2017 Jan; 40(1):53-55. PubMed ID: 28072886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.